| All Releases |
|---|
 |
Salix and Progenics Announce FDA Advisory Committee to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain
Jun 11, 2013
|
16.0 KB
|
| |
RALEIGH, N.C. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals
(NASDAQ:PGNX) today announced that the FDA is seeking input from an
Advisory Committee on Salix's Supplemental New Drug Application (sNDA)
for RELISTOR® (methylnaltrexone bromide) Subcut...
|
|
|
Progenics Pharmaceuticals Presents PSMA-Related Data at SNMMI 2013
Jun 10, 2013
|
20.0 KB
|
| |
TARRYTOWN, N.Y., June 10, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has reported findings from studies of two of its oncology product candidates at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada.
Data from studies of MIP-1095,...
|
|
|
Progenics Pharmaceuticals' Data From a Phase 1 Study of PSMA ADC Presented at ASCO 2013
Jun 1, 2013
|
20.5 KB
|
| |
TARRYTOWN, N.Y., June 1, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today reported findings from the phase 1 clinical trial in prostate cancer patients of its PSMA ADC compound at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Two additional abstracts related to PSMA ADC also were...
|
|
|
Progenics Pharmaceuticals to Present at Jefferies Global Healthcare Conference
May 31, 2013
|
16.3 KB
|
| |
TARRYTOWN, N.Y., May 31, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a presentation on Wednesday, June 5th at 3:00 PM EDT at the Jefferies Global Healthcare Conference in New York City. The company overview will be webcast live via a link on the Events page of Progenics' web...
|
|
|
Progenics Pharmaceuticals Added to the NASDAQ Biotechnology Index
May 17, 2013
|
14.8 KB
|
| |
TARRYTOWN, N.Y., May 17, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:^NBI) effective prior to market open on Monday, May 20.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ ...
|
|
|
Progenics Pharmaceuticals Announces First Quarter 2013 Financial Results
May 10, 2013
|
24.5 KB
|
| |
TARRYTOWN, N.Y., May 10, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the quarter ended March 31.
Net loss for the quarter was $11.3 million or $0.22 diluted per share, compared to net loss of $13.1 million or $0.39 diluted per share in the 2012 period, due primarily to...
|
|
|
Progenics Pharmaceuticals to Host Conference Call to Review First Quarter 2013 Financial Results on May 10
May 6, 2013
|
13.7 KB
|
| |
TARRYTOWN, N.Y., May 6, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss financial results for the first quarter 2013 on Friday, May 10, 2013 at 8:30 a.m. ET.
To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international...
|
|
|
Progenics Pharmaceuticals to Present at Needham Healthcare Conference
Apr 24, 2013
|
16.7 KB
|
| |
TARRYTOWN, N.Y., April 24, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a presentation on Tuesday, April 30 at 3:00 PM EDT at Needham & Company's 12th Annual Healthcare Conference in New York City. The company overview will be webcast live via a link on the Events page of Pro...
|
|
|
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2012 Financial Results
Mar 15, 2013
|
27.9 KB
|
| |
TARRYTOWN, N.Y., March 15, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the fourth quarter and year end 2012.
Net loss for the fourth quarter was $0.3 million or $0.01 diluted per share, compared to net loss of $10.7 million or $0.32 diluted per share in the 2011 period...
|
|
|
Progenics Pharmaceuticals to Host Conference Call to Review Fourth Quarter Financial Results on March 15
Mar 8, 2013
|
13.8 KB
|
| |
TARRYTOWN, N.Y., March 8, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the fourth quarter 2012 on Friday, March 15, 2013 at 8:30 a.m. ET.
To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (inte...
|
|
|
Progenics Pharmaceuticals' Novel Small Molecule Drugs Targeting PSMA Successfully Visualize Prostate Cancer
Mar 5, 2013
|
21.3 KB
|
| |
— Positive Data Reported in The Journal of Nuclear Medicine —
— Global Phase 2 Imaging Trial of Next Generation Molecule Underway —
TARRYTOWN, N.Y., March 5, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) reported positive clinical data from a study of two novel radiolabeled small mole...
|
|
|
Progenics Pharmaceuticals Presents Updated Data From Phase 1 Study of PSMA ADC
Feb 14, 2013
|
18.3 KB
|
| |
- Outcomes From Clinical Study in Prostate Cancer Presented at Genitourinary Cancers Symposium -
TARRYTOWN, N.Y., Feb. 14, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today reported positive clinical data from a completed phase 1 study of PSMA ADC, an antibody-drug conjugate (ADC) designed to selectively deliver c...
|
|
|
Progenics Acquires Molecular Insight Pharmaceuticals to Expand Oncology-Focused Pipeline
Jan 22, 2013
|
18.5 KB
|
| |
— Gains Therapeutic and Diagnostic Compounds That Deepen Strategic Focus on PSMA Target —
— Adds Late-Stage Ultra-Orphan Oncology Candidate —
TARRYTOWN, N.Y., Jan. 22, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has acquired Molecular Insight Pharmaceuticals,...
|
|
|
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Nov 29, 2012
|
20.7 KB
|
| |
TARRYTOWN, N.Y., Nov. 29, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today the pricing of an underwritten public offering of 11,000,000 primary shares of its common stock at a public offering price of $2.00 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions ...
|
|
|
Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Nov 28, 2012
|
20.2 KB
|
| |
TARRYTOWN, N.Y., Nov. 28, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective registration statement in an underwritten public offering. Progenics also intends to grant the underwriter a 30-day ...
|
|
|
Progenics Pharmaceuticals Announces Third Quarter 2012 Financial Results
Nov 8, 2012
|
31.5 KB
|
| |
TARRYTOWN, N.Y., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the third quarter and first nine months of 2012.
Net loss for the third quarter of 2012 was $11.3 million or $0.33 basic and diluted per share, compared to net loss of $11.4 million or $0.34 per share...
|
|
|
Progenics Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
Nov 6, 2012
|
17.1 KB
|
| |
TARRYTOWN, N.Y., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a presentation on Tuesday, November 13 at 3:30 PM EST at the Lazard Capital Markets 9th Annual Healthcare Conference in New York City. Mr. Baker will provide a company overview, which will be webcast live v...
|
|
|
Progenics Pharmaceuticals to Host Conference Call to Review Third Quarter Financial Results on November 8
Nov 2, 2012
|
13.8 KB
|
| |
TARRYTOWN, N.Y., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the third quarter on Thursday, November 8, 2012 at 8:30 a.m. EST.
To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (intern...
|
|
|
Progenics Pharmaceuticals Initiates Phase 2 Clinical Trial of PSMA ADC in Prostate Cancer Patients
Sep 28, 2012
|
21.0 KB
|
| |
TARRYTOWN, N.Y., Sept. 28, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) has opened enrollment in a phase 2 study in prostate cancer patients of its PSMA ADC compound. PSMA ADC is a targeted anti-cancer therapeutic that uses a monoclonal antibody to deliver a cell-killing drug to malignant cells.
"New prostate cance...
|
|
|
Progenics Pharmaceuticals Provides Corporate Update
Sep 20, 2012
|
20.4 KB
|
| |
TARRYTOWN, N.Y., Sept. 20, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced a companywide restructuring, including a reduction of its workforce. The company will continue to focus its resources and efforts on its oncology programs, particularly an upcoming phase 2 study of PSMA ADC in prostate cancer patients.
...
|
|
|
